FDA Approves Manufacturing Plan For Menerba, Bionovo's Menopausal Hot Flash Drug Candidate
October 16, 2010 by · Leave a Comment
Bionovo, Inc. (Nasdaq: BNVI, BNVID) announced that the U.S. Food and Drug Administration (FDA) accepted the Company’s Chemistry, Manufacturing and Controls (CMC) plan for its lead drug candidate, Menerba®, in a Type “B” or “End of Phase 2″ meeting. With this designation, the decisions and agreements are now considered binding on the Company and the FDA…
FDA Approves Manufacturing Plan For Menerba, Bionovo's Menopausal Hot Flash Drug Candidate
October 5, 2010 by · Leave a Comment
Bionovo, Inc. (Nasdaq: BNVI, BNVID) announced that the U.S. Food and Drug Administration (FDA) accepted the Company’s Chemistry, Manufacturing and Controls (CMC) plan for its lead drug candidate, Menerba®, in a Type “B” or “End of Phase 2″ meeting. With this designation, the decisions and agreements are now considered binding on the Company and the FDA…
FDA Approves Manufacturing Plan For Menerba, Bionovo's Menopausal Hot Flash Drug Candidate
September 26, 2010 by · Leave a Comment
Bionovo, Inc. (Nasdaq: BNVI, BNVID) announced that the U.S. Food and Drug Administration (FDA) accepted the Company’s Chemistry, Manufacturing and Controls (CMC) plan for its lead drug candidate, Menerba®, in a Type “B” or “End of Phase 2″ meeting. With this designation, the decisions and agreements are now considered binding on the Company and the FDA…
Bionovo Announces Reverse Stock Split
August 31, 2010 by · Leave a Comment
EMERYVILLE, Calif., Aug. 30 /PRNewswire-FirstCall/ — Bionovo, Inc. (Nasdaq: BNVI, BNVID) announced today that it will effect a 1-for-5 reverse stock split, that will become effective with the opening of trading on August 31, 2010. The primary objective in effecting a reverse stock split at this time is to better enable the company to maintain the listing of its common stock on The NASDAQ …
Bionovo Receives Positive Guidance from FDA on Menerba®
August 31, 2010 by · Leave a Comment
EMERYVILLE, Calif., Aug. 30 /PRNewswire-FirstCall/ — Bionovo, Inc. (Nasdaq: BNVI, BNVID) announced today that it has received positive guidance from the U.S. Food and Drug Administration (FDA) regarding the Company’s Chemistry, Manufacturing and Controls (CMC) plan for its lead drug candidate Menerba®. The FDA indicated its agreement with Bionovo’s plan. This agreement provides the necessary …
